Neuroanatomical distribution of receptors for a novel voltage-sensitive calcium-channel antagonist, SNX-230 (ω-conopeptide MVIIC)

doi:10.1016/0006-8993(94)90398-0

Brain Research

Volume 653, Issues 1–2, 8 August 1994, Pages 258-266

https://doi.org/10.1016/0006-8993(94)90398-0 Get rights and content

Abstract

Neuronal voltage-sensitive calcium channels (VSCCs) are a diverse family of proteins that regulate entry of Ca²⁺ into neurons. Selective antagonists of VSCCs have proven to be powerful pharmacological tools for identifying and characterizing these channels. A new VSCC antagonist, SNX-230 (also known as ω-conopeptide MVIIC), binds with high affinity to receptors in rat brain and blocks one or more high-threshold VSCCs that are neither L- nor N-type. We have defined the neuroanatomical distribution of the high-affinity non-L, non-N VSCC receptors for SNX-230 using [¹²⁵I]SNX-230 bound to rat brain sections and compared it with that of [¹²⁵I]SNX-111, a reversible blocker of N-type VSCCs. Highest densities of binding for both ligands were seen in areas rich in synaptic connections, such as the oriens, radiatum and molecular layers of the hippocampus. In general, the density of [¹²⁵I]SNX-230-binding was higher in cerebellum compared with that in forebrain. In contrast, this general distribution of density was reversed for [¹²⁵I]SNX-111. In the glomeruli of the olfactory bulb, binding of [¹²⁵I]SNX-230 was undetectable compared with the high density of [¹²⁵I]SNX-111-binding. Differential localization of the two ligands was also seen in cervical spinal cord. The clearly different localization of [¹²⁵I]SNX-230 compared with that of [¹²⁵I]SNX-111 in the olfactory bulb and spinal cord suggested that the binding sites for [¹²⁵I]SNX-230 in other brain regions, while co-localized macroscopically, are also distinct from those for [¹²⁵I]SNX-111. This was confirmed when addition of saturating concentrations of SNX-111 did not affect the distribution pattern of [¹²⁵I]SNX-230-binding. These observations demonstrate that the high-affinity [¹²⁵I]SNX-230 receptors in the brain and those of the N-type VSCCs are distinct molecular entities. Thus, SNX-230 (ω-MVIIC) offers a useful ligand for investigating the distribution and functions of non-L-, non-N-type VSCCs in the brain.

Reference (30)

AhlijanianM.K. et al.
Subunit structure and localization of dihydropyridine-sensitive calcium channels on mammalian brain, spinal cord and retina
Neuron
(1990)
FeldmanD.H. et al.
OmegaConus geographus toxin: a peptide that blocks calcium channels
FEBS Lett.
(1987)
GouldR. et al.
Autoradiographic localization of calcium channel antagonist receptors in rat brain with [³H]-nitrendipine
Brain Res.
(1985)
HillyardD.R. et al.
A newConus peptide ligand for mammalian presynaptic Ca²⁺ channels
Neuron
(1992)
KerrL.M. et al.
Autoradiographic localization of calcium channels with [¹²⁵I]-ω-conotoxin in rat brain
Eur. J. Pharmacol.
(1988)
SatherW.A. et al.
Distinctive biophysical and pharmacological properties of class A (B1) calcium channelα₁ subunits
Neuron
(1993)
StoehrS.J. et al.
Characteristics of [¹²⁵I]-omega conotoxin MVIIA binding to rat neocortical membranes
Neurosci. Lett.
(1993)
TakemuraM. et al.
Autoradiographic visualization in rat brain of receptors for ω-conotoxin GVIA, a newly discovered calcium antagonist
Brain Res.
(1988)
TsienR.W. et al.
Molecular diversity of voltage dependent Ca²⁺ channels
Trends Pharmacol. Sci.
(1991)
WestenbroekR.E. et al.
Biochemical properties and subcellular distribution of an N-type calcium channelα₁ subunit
Neuron
(1992)

Bowersox, S.S., Miljanich, G.P., Suguira, Y., Li C., Nadasdi, L., Hoffman, B.B., Ramachandran, J. and Ko, C-P.,...

DoroshenkoP.A. et al.

Pharmacological properties and localization of calcium channel types in the cerebellar cortex

Soc. Neurosci. Abstr.

(1993)

Gaur, S., Newcomb, R., Benjamin, R., Bell, J., Ramachandran, J. and Miljanich, G.P., Calcium channel antagonist...

Kristipati, R., Nadasdi, L., Tarczy-Hornoch, K., Miljanich, G.P., Ramachandran, J. and Bell, J.R., Characterization of...

Malmberg, A.B. and Yaksh, T.L., Voltage sensitive calcium channels in spinal nociceptive processing: blockade of N-type...

Cited by (116)

Upregulation of N-type calcium channels in the soma of uninjured dorsal root ganglion neurons contributes to neuropathic pain by increasing neuronal excitability following peripheral nerve injury
2018, Brain, Behavior, and Immunity
Citation Excerpt :
At present, the therapeutic effect is explained by the fact that Cav2.2 channels are expressed in presynaptic terminals, and opening the channel subtype is essential for release of neurotransmitters such as glutamate, substance P and CGRP (see (Perret and Luo, 2009) for a review). While Cav2.2 channels are also expressed in the soma of DRG neurons (Gohil et al., 1994; Kerr et al., 1988), their function is largely unknown. In the present study, we found that Cav2.2 protein was upregulated in the soma of uninjured DRG neurons in both L5-SNL and L5-VRT models of neuropathic pain (Figs. 1–3).
N-type voltage-gated calcium (Cav2.2) channels are expressed in the central terminals of dorsal root ganglion (DRG) neurons, and are critical for neurotransmitter release. Cav2.2 channels are also expressed in the soma of DRG neurons, where their function remains largely unknown. Here, we showed that Cav2.2 was upregulated in the soma of uninjured L4 DRG neurons, but downregulated in those of injured L5 DRG neurons following L5 spinal nerve ligation (L5-SNL). Local application of specific Cav2.2 blockers (ω-conotoxin GVIA, 1–100 μM or ZC88, 10–1000 μM) onto L4 and 6 DRGs on the operated side, but not the contralateral side, dose-dependently reversed mechanical allodynia induced by L5-SNL. Patch clamp recordings revealed that both ω-conotoxin GVIA (1 μM) and ZC88 (10 μM) depressed hyperexcitability in L4 but not in L5 DRG neurons of L5-SNL rats. Consistent with this, knockdown of Cav2.2 in L4 DRG neurons with AAV-Cav2.2 shRNA substantially prevented L5-SNL-induced mechanical allodynia and hyperexcitability of L4 DRG neurons. Furthermore, in L5-SNL rats, interleukin-1 beta (IL-1β) and IL-10 were upregulated in L4 DRGs and L5 DRGs, respectively. Intrathecal injection of IL-1β induced mechanical allodynia and Cav2.2 upregulation in bilateral L4–6 DRGs of naïve rats, whereas injection of IL-10 substantially prevented mechanical allodynia and Cav2.2 upregulation in L4 DRGs in L5-SNL rats. Finally, in cultured DRG neurons, Cav2.2 was dose-dependently upregulated by IL-1β and downregulated by IL-10. These data indicate that the upregulation of Cav2.2 in uninjured DRG neurons via IL-1β over-production contributes to neuropathic pain by increasing neuronal excitability following peripheral nerve injury.
N- and L-type calcium channels blocker cilnidipine ameliorates neuropathic pain
2016, European Journal of Pharmacology
Cilnidipine is a dihydropyridine derivative that inhibits N-type and L-type voltage-gated Ca²⁺ channels (VDCCs). We recently reported that a selective N-type VDCC blocker attenuated the spinal long-term potentiation (LTP) of C-fiber-evoked field potentials recorded in the spinal dorsal horn of rats, which served as a model for examining synaptic function during central pain sensitization. In this study, we investigated the effects of cilnidipine on the changes related to neuropathic pain induced by nerve injury. Mechanical allodynia and hyperalgesia were evaluated by von Frey test and pin prick test, respectively. Spinal LTP of C-fiber-evoked field potentials were evaluated by in vivo electrophysiology. Intrathecally administrated cilnidipine attenuated mechanical allodynia and hyperalgesia in the spared nerve injury mouse model. Using in vivo electrophysiology in rats, cilnidipine (10 µm) administered spinally inhibited the induction and maintenance of high-frequency stimulation-induced LTP of C-fiber-evoked field potentials, while basal C-fiber-evoked field potentials in naïve rats were unaffected. The basal C-fiber-evoked field potentials in nerve-injured rats were strongly inhibited by cilnidipine. Treatment with a specific N-type VDCC blocker, ω-conotoxin GVIA, which reportedly attenuates C-fiber-evoked field potentials both before and after the induction of LTP, attenuated mechanical allodynia and hyperalgesia in nerve-injured mice. By contrast, an L-type VDCC blocker, nicardipine attenuated only mechanical hyperalgesia, but not mechanical allodynia in nerve-injured mice, and also attenuated the established LTP of C-fiber-evoked field potentials in rats. These results suggested that N-type and L-type VDCC blockers may effectively alleviate the hyperalgesia and allodynia associated with neuropathic pain without affecting normal pain perception.
Characterization of the triazine, T4, a representative from a novel series of Ca<inf>V</inf>2 inhibitors with strong state-dependence, poor use-dependence, and distinctively fast kinetics
2014, European Journal of Pharmacology
There is strong pharmacological, biological, and genetic evidence supporting the role of N-type calcium channels (Ca_V2.2) in nociception. There is also human validation data from ziconotide, the Ca_V2.2-selective peptidyl inhibitor used clinically to treat refractory pain. Unfortunately, ziconotide utility is limited by its narrow therapeutic window and required intrathecal route of administration. A major focus has been placed on identifying state-dependent Ca_V2.2 inhibitors to improve safety margins. Much less attention, however, has been given to characterizing the kinetics of Ca_V2.2 inhibitors as a means to further differentiate compounds and maximize therapeutic potential. Here we provide a detailed characterization of the Ca_V2.2 inhibitor T4 in terms of its state-dependence, use-dependence, kinetics, and mechanism of inhibition. Compound T4 displayed a >20-fold difference in potency when measured under inactivating conditions (IC₅₀=1.1 μM) as compared to closed-state conditions (IC₅₀=25 μM). At 3 μM, T4 produced a 15-fold hyperpolarizing shift in the inactivation curve for Ca_V2.2 while having no effect on channel activation. To assess the kinetic properties of T4 in a more physiological manner, its inhibition kinetics were assessed at 32 °C using 2 mM Ca²⁺ as the charge carrier. Surprisingly, the repriming rate for Ca_V2.2 channels at hyperpolarized potentials was similar in both the presence and absence of T4. This was in contrast to other compounds which markedly delayed repriming. Furthermore, T4 inhibited Ca_V2.2 channels more potently when channel inactivation was driven through a tonic sub-threshold depolarization rather than through a use-dependent protocol, despite similar levels of inactivation.
Mechanisms of conotoxin inhibition of N-type (Ca<inf>v</inf>2.2) calcium channels
2013, Biochimica et Biophysica Acta - Biomembranes
N-type (Ca_v2.2) voltage-gated calcium channels (VGCC) transduce electrical activity into other cellular functions, regulate calcium homeostasis and play a major role in processing pain information. Although the distribution and function of these channels vary widely among different classes of neurons, they are predominantly expressed in nerve terminals, where they control neurotransmitter release. To date, genetic and pharmacological studies have identified that high-threshold, N-type VGCCs are important for pain sensation in disease models. This suggests that N-type VGCC inhibitors or modulators could be developed into useful drugs to treat neuropathic pain. This review discusses the role of N-type (Ca_v2.2) VGCCs in nociception and pain transmission through primary sensory dorsal root ganglion (DRG) neurons (nociceptors). It also outlines the potent and selective inhibition of N-type VGCCs by conotoxins, small disulfide-rich peptides isolated from the venom of marine cone snails. Of these conotoxins, ω-conotoxins are selective N-type VGCC antagonists that preferentially block nociception in inflammatory pain models, and allodynia and/or hyperalgesia in neuropathic pain models. Another conotoxin family, α-conotoxins, were initially proposed as competitive antagonists of muscle and neuronal nicotinic acetylcholine receptors (nAChR). Surprisingly, however, α-conotoxins Vc1.1 and RgIA, also potently inhibit N-type VGCC currents in the sensory DRG neurons of rodents and α9 nAChR knockout mice, via intracellular signaling mediated by G protein-coupled GABA_B receptors. Understanding how conotoxins inhibit VGCCs is critical for developing these peptides into analgesics and may result in better pain management. This article is part of a Special Issue entitled: Calcium channels.
Spinal Mechanisms of Pain and Analgesia
2013, Pain Practice
Chronic pain—especially that which is refractory to conventional treatment—presents particular challenges to physicians and patients. Examination of the molecular and cellular mechanisms involved in this pathophysiology suggests that spinal instillation of therapeutic agents may offer an effective treatment option through the modification of the processing and sensation of chronic pain. Intrathecal therapy, used alone or in combination with other analgesic agents, may reduce chronic pain by attenuating both pre- and postsynaptic activities. This article reviews chronic pain pathophysiology and the mechanisms whereby spinally administered analgesics may modify chronic pain. Available treatment options are also considered, including recommendations from the 2007 Polyanalgesic Consensus Conference (PACC) guidelines on the use of intrathecal agents for nociceptive, neuropathic, and mixed pain.
Antihypertensives
2024, Pharmacology in Veterinary Anesthesia and Analgesia

View all citing articles on Scopus

View full text

Neuroanatomical distribution of receptors for a novel voltage-sensitive calcium-channel antagonist, SNX-230 (ω-conopeptide MVIIC)

Abstract

Neuron

FEBS Lett.

Brain Res.

Neuron

Eur. J. Pharmacol.

Neuron

Neurosci. Lett.

Brain Res.

Trends Pharmacol. Sci.

Neuron

Pharmacological properties and localization of calcium channel types in the cerebellar cortex

Soc. Neurosci. Abstr.